Years of life lost due to bladder cancer among the inhabitants of Poland in the years 2000 to 2014 (original) (raw)
Related papers
ears of life lost due to bladder cancer among the inhabitants of Poland in the years 2000 to 2014
Central European Journal of Urology, 2017
Introduction The aim of the study is to evaluate the number of years of life lost in inhabitants of Poland due to bladder cancer (BC), identify trends of the mortality and calculate the pace of change which has happened over the period of the first fifteen years of the 21 st century. Material and methods The study material was a database including 44,283 death certificates of Polish inhabitants who died due to bladder cancer in the period 2000-2014. The number of years of life lost were calculated using the SEYLL indices: SEYLLp (Standard Expected Years of Life Lost per living person) and SEYLLd (Standard Expected Years of Life Lost per death). Results The crude death rates (CDR) index increased from 10.79 per 100,000 males in 2000 to 14.30 in 2014 (Annual Percentage Change [APC] = 2.1%, p <0.05). In women, the group value of the CDR index increased from 2.50 in 2000 to 3.83 in 2014 (APC = 2.9%, p <0.05). The standardized death rates (SDR) index fell from 23.27 in 2000 to 22.48 in 2014 (APC =-0.1%, p >0.05) in men, but rose from 3.54 in 2000 to 3.83 in 2014 (APC = 0.4%, p <0.05) in women. The SEYLLp index (per 100,000 population) due to bladder cancer in Poland increased from 202.9 in 2000 to 243.4 in 2014 (APC = 1.3%, p <0.05) in men, and from 40.4 in 2000 to 60.1 in 2014 (APC = 2.7%, p <0.05) in women. Conclusions Despite the prolongation of patient life, as shown by the SEYLLd factor, Polish patients still lose too many years of life due to BC than compared to United States patients.
Declining mortality from bladder cancer in Europe
BJU International, 2007
To update trends in bladder cancer mortality in 32 European countries and the European Union (EU) as a whole, as mortality from bladder cancer has been declining in most of Western Europe since the early 1990 s, but it has still been increasing in several central and eastern European countries up to the mid 1990 s. We used data from the World Health Organization (WHO) database over the period 1970-2004. Significant changes in mortality rates were identified using join-point regression analysis. In the EU overall (27 countries), bladder cancer mortality rates (age-standardized, world standard population) were stable up to the early 1990 s at approximately 7/100,000 men and 1.5/100,000 women, and declined thereafter by approximately 16% in men and 12% in women, to reach values of 6 and 1.3/100,000, respectively, in the early years of the present decade. Over recent years, most countries showed decreasing trends, except Croatia and Poland in both sexes, Romania in men and Denmark in women. Truncated rates at age 35-64 years were lower in both sexes and trends for men were more favourable, with an overall decrease by &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;21% during the last decade. Join point regression analysis indicates that, for most countries, the trends were more favourable over recent calendar periods. The favourable trends in men are partly or largely due to the recent declines in the prevalence of smoking in European men, together with reduced occupational exposure to occupational carcinogens. The decreases in women are more difficult to explain. Better control of urinary tract infections has probably played a role, while the role of diet and other potential urinary tract carcinogens remains undefined.
Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019, 2021
ABSTRACT Introduction The current study determined the level and trends associated with the incidence, death and disability rates for bladder cancer and its attributable risk factors in 204 countries and territories, from 1990 to 2019, by age, sex and sociodemographic index (SDI; a composite measure of sociodemographic factors). Methods Various data sources from different countries, including vital registration and cancer registries were used to generate estimates. Mortality data and incidence data transformed to mortality estimates using the mortality to incidence ratio (MIR) were used in a cause of death ensemble model to estimate mortality. Mortality estimates were divided by the MIR to produce incidence estimates. Prevalence was calculated using incidence and MIR-based survival estimates. Age-specific mortality and standardised life expectancy were used to estimate years of life lost (YLLs). Prevalence was multiplied by disability weights to estimate years lived with disability (YLDs), while disabilityadjusted life years (DALYs) are the sum of the YLLs and YLDs. All estimates were presented as counts and agestandardised rates per 100 000 population. Results Globally, there were 524 000 bladder cancer incident cases (95% uncertainty interval 476 000 to 569 000) and 229 000 bladder cancer deaths (211 000 to 243 000) in 2019. Age-standardised death rate decreased by 15.7% (8.6 to 21.0), during the period 1990–2019. Bladder cancer accounted for 4.39million (4.09 to 4.70) DALYs in 2019, and the age-standardised DALY rate decreased significantly by 18.6% (11.2 to 24.3) during the period 1990–2019. In 2019, Monaco had the highest agestandardised incidence rate (31.9 cases (23.3 to 56.9) per 100 000), while Lebanon had the highest age-standardised death rate (10.4 (8.1 to 13.7)). Cabo Verde had the highest increase in age-standardised incidence (284.2% (214.1 to 362.8)) and death rates (190.3% (139.3 to 251.1)) between 1990 and 2019. In 2019, the global age-standardised incidence and death rates were higher among males than females, across all age groups and peaked in the 95+ age group. Globally, 36.8% (28.5 to 44.0) of bladder cancer DALYs were attributable to smoking, more so in males than females (43.7% (34.0 to 51.8) vs 15.2% (10.9 to 19.4)). In addition, 9.1% (1.9 to 19.6) of the DALYs were attributable to elevated fasting plasma glucose (FPG) (males 9.3% (1.6 to 20.9); females 8.4% (1.6 to 19.1)). Conclusions There was considerable variation in the burden of bladder cancer between countries during the period 1990–2019. Although there was a clear global decrease in the age-standardised death, and DALY rates, some countries experienced an increase in these rates. National policy makers should learn from these differences, and allocate resources for preventative measures, based on their country-specific estimates. In addition, smoking and elevated FPG play an important role in the burden of bladder cancer and need to be addressed with prevention programmes.
Mortality Trends Related to Bladder Cancer in Spain, 1999–2018
Journal of Clinical Medicine, 2022
Bladder cancer (BC) is an important cause of premature mortality (PM, <75 years). Spain has one of the highest BC mortality rates in Europe. The objective of this study was to analyse BC mortality trends between 1999 and 2018 in Spain. The study was based on data from the National Institute of Statistics (Instituto Nacional de Estadística—INE). Age-adjusted mortality rates (AAMRs) were calculated by sex and age group. A trend analysis was performed using Joinpoint regression models and years of potential life lost (YPLL). Mortality in men resulting from BC decreased in all age groups studied. This was not observed in women, for whom mortality only decreased in the ≥75 age group. Deaths due to BC occurred prematurely in 38.6% of men and in 23.8% of women, which indicated a greater impact on YPLL in men compared to women. Over the last 20 years, there has been a significant decrease in BC mortality rate, except in women under 75 years of age. Despite this temporal trend of decreasi...
Purpose: To study whether the incidence of bladder cancer in an industrialized area in North-Eastern Spain remains as high as in the nineties.Methods: Patients diagnosed with histologically confirmed primary bladder cancer, during 2018-2019, in an area in North-Eastern Spain (430,883 inhabitants) were included. Crude incidence rates were estimated per 100,000 person-year based on the number of individuals getting their first diagnosis. Direct age-standardized incidence rates were calculated applying both the European and the World Standard Populations.Results: 295 patients were included (mean age 72.5±10.3 years; 89.8% men). The crude rate was 62.6 (95%CI:55.0-70.1) for men and 6.8 (95%CI:4.4-9.3) for women. The annual rate adjusted to the European Standard Population was 85.3 (95%CI:75.0-95.5) for men and 7.0 (95%CI:4.5-9.5) for women, and adjusted to the World Standard Population, 31.7 (95%CI:27.9-35.5) and 2.9 (95%CI:1.8-3.9) respectively. Conclusion: The incidence of bladder c...
Essentials of bladder cancer worldwide: incidence, mortality rate and risk factors
Biomedical Research and Therapy
Bladder cancer (BC) is the sixth most common cancer in the world. An increase in the incidence and recurrence of BC has led to massive pressure on health care systems. Studies have shown that the geographical and ethical distributions of BC are variable in different parts of the world. However, most studies have focused more on clinical challenges and treatment strategies in BC management. Due to the limited number of studies conducted on the incidence rate, mortality and risk factors of BC worldwide, it is necessary to carry out studies in these areas. Therefore, the aim of this study was to determine the global incidence rate, mortality rate and risk factors for BC.
Trend of bladder cancer mortality in Iran (2006 to 2010)
2015
Background and aims: Bladder cancer is the most common tumor of the urinary tract and the ninth cancer in terms of incidence in both sexes in the world. Bladder cancer is the second most common cancer among men in Iran. The most important risk factors which attribute to the incidence of bladder cancer are tobacco usage, exposure to industrial materials, and chronic infection by Schistsoma. This study aimed to investigate the trend of death from bladder cancer in Iran. Methods: This study was conducted by the use of data on mortality in Iran during 2006-10. Data on mortality from cancer within the study period were collected and entered on a pre-designed form. Mortality rates per 105 persons were calculated by age group and sex, and the trend of mortality from this cancer was determined. Results: The results from the calculation of mortality rates per 105 persons indicated that the death rate from bladder cancer is reduced from 1.12 to 1.09. The mortality rates during all the years ...
Estimation of Total Burden of Bladder Cancer in Brazil – An Economic and Clinical Approach
Value in Health, 2018
Impairment-General Health questionnaire), multiplied by the Brazilian GDP per capita. For DC estimation, patients were identifying by ICD-10 code and procedures for BC treatment were obtained from national databases (Inpatient Information System, SIH/SUS and Outpatient Information System, SIA/SUS). The clinical impact of BC was analyzed by Disability Adjusted Life Years (DALYs). Years of life lost (YLL) was calculated based on the life expectancy (Brazilian Institute of Geography and Statistics) and BC mortality (SIM/DATASUS). Age-weighting and 5% discount rate were used. Years lived with disability (YLD) were calculated through an incidence perspective based on disability weights presented on Global Burden of Disease Study (2013) and incidence from Brazilian National Institute of Cancer. All analysis was based on 2014 data. ReSultS: In 2014, BC resulted in a loss of 27,738 years due to the premature death and 12,402 due to disabilities, resulting in 40,140 DALYs. Direct cost attribute to BC treatment was US$29,879,165, whereas indirect cost was estimation was of US$ 76,996,523. ConCluSionS: Despite the relative low incidence and age of patients affected, BC results in a relevant clinical and economic burden to the Brazilian society. The development of strategies related to prevention and early diagnosis is essential.
Survival analysis of patients with bladder cancer, life table approach
Journal of Mid-life Health, 2012
Background: Bladder cancer is the fourth most common malignancy in men and the eighth most common in women. It causes 8% of all malignancies in men and 3% of all malignancies in women. The trend of bladder cancer is increasing in Iran. This study was conducted to estimate the survival rate of bladder cancer based on life table method. Materials and Methods: In this study, at first, data were collected based on individual variables of 514 patients suffering from bladder cancer and referred them to cancer registry center of Shiraz University of Medical Sciences from 2001-2009. Data were collected at two stages and analyzed by life table method and Wilcox on test. Significant level considered at 0.05. Results: Our findings showed that probability of survival accumulation at the end of 1, 3, 5, 10 years in patients with bladder cancer were equal to 0.8989, 0.7132, 0.5752 and 0.2459 respectively. There was significant difference in survival rate among age groups and treatment types (P < 0.05). However, we did not observe any difference in survival time based on smoking (P = 0.578), alcohol (P = 0.419) and education level (P = 0.371) of patients. Conclusion: The overall survival rate of bladder cancer in the present study was less than other areas. Patients' age and treatment type were the influential factor in survival time. So continuous screening for early diagnosis suggested for older people.